CareFirst BlueCross BlueShield announces coverage of new exosome liquid biopsy tests for prostate cancer

January 10, 2018 Leave a comment 2,261 Views

CareFirst BlueCross BlueShield (CareFirst), today announced that it has reached a positive coverage decision for the ExoDx® Prostate(IntelliScore) or EPI test – meaning that the test will be covered for CareFirst members beginning in 2018. This coverage decision is based ...

Exosome RNA Exosome RNA Research & Industry News

Tag Archives: EPI test

CareFirst BlueCross BlueShield announces coverage of new exosome liquid biopsy tests for prostate cancer

Capricor Therapeutics (CAPR) Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock

Longitudinal stability of urinary extracellular vesicle protein patterns within and between individuals

ExoHCR – a sensitive assay to profile PD-L1 level on tumor exosomes for immunotherapeutic prognosis

Nanoparticles to help evaluate the effectiveness of radiation therapy for cervical cancer

Exosome-Based Vaccines: History, Current State, and Clinical Trials

Exosome formulation developed to deliver antibodies for choroidal neovascularization therapy